Mental Disorders and Interferon Nontreatment in Hepatitis C Virus Infection-a Population Based Cohort Study
- PMID: 32151125
- PMCID: PMC7113179
- DOI: 10.30773/pi.2019.0254
Mental Disorders and Interferon Nontreatment in Hepatitis C Virus Infection-a Population Based Cohort Study
Abstract
Objective: This study investigates the association between mental disorders and interferon nontreatment in patients with chronic hepatitis C virus (HCV) infection in a large national sample.
Methods: Using the National Health Insurance Research Database of Taiwan, we conducted a nationwide population-based study. Each case was matched to five controls by age, sex, urbanization, and income. Conditional logistic regression was used to assess odds of HCV nontreatment in different mental disorders.
Results: From 1999 to 2013, we identified 92,970 subjects with HCV infection and 15,495 HCV cases (16.7%) had received IFN therapy. Other than chronic obstructive pulmonary disease, the medical diseases and mental disorders were significantly different between IFN and non-IFN treated HCV patients. After adjusting for medical diseases, depressive disorder and anxiety disorder was positively associated with receiving IFN therapy. Patients with schizophrenia, bipolar disorders and alcohol use disorders were significantly less likely to receive interferon. Antidepressant exposure (cumulative daily exposure or cumulative daily dose) was associated with lower odds of IFN treatment.
Conclusion: Our nationwide cohort study demonstrated that INF nontreatment rate was lower in certain mental disorders. Antidepressant exposure might lower the chance of receiving IFN treatment. Our results may help to identify and to overcome the obstacles for HCV treatment and further apply to DAAs regimen.
Keywords: Anxiety; Depression; Hepatitis C; Interferon non-treatment; Mental disorders.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures
Similar articles
-
Depression-free after Interferon-α exposure indicates less incidence of depressive disorder: A longitudinal study in Taiwan.Brain Behav Immun. 2020 Aug;88:125-131. doi: 10.1016/j.bbi.2020.05.044. Epub 2020 May 17. Brain Behav Immun. 2020. PMID: 32434045
-
Antidepressant use and hepatocellular carcinoma in patients with hepatitis C who had received interferon therapy: A population-based cohort study.J Affect Disord. 2019 Jun 15;253:147-153. doi: 10.1016/j.jad.2019.04.093. Epub 2019 Apr 22. J Affect Disord. 2019. PMID: 31035215
-
Recurrence of depressive disorders after interferon-induced depression.Transl Psychiatry. 2017 Feb 7;7(2):e1026. doi: 10.1038/tp.2016.274. Transl Psychiatry. 2017. PMID: 28170005 Free PMC article.
-
Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction.Clin Infect Dis. 2013 Aug;57 Suppl 2:S111-7. doi: 10.1093/cid/cit266. Clin Infect Dis. 2013. PMID: 23884058 Review.
-
Treatment of chronic hepatitis C in southern Taiwan.Intervirology. 2006;49(1-2):99-106. doi: 10.1159/000087271. Intervirology. 2006. PMID: 16166797 Review.
References
-
- Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095–2100. - PubMed
-
- NIH Consensus Statement on Management of Hepatitis C 2002. NIH Consens State Sci Statements. 2002;19:1–46. - PubMed
-
- Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2005;3:S89–S91. - PubMed
-
- Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–520. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources